Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer - read this article along with other careers information, tips and advice on BioSpace
United States Anwaar Saeed Danielm Schmitt Razelle Kurzrock Actuate Therapeutics Inc Retifanlimab Incyte Corporation
Source: biospace.com